BridgeBio Oncology Secures $450M SPAC Deal to Advance KRAS Inhibitor Pipeline
• BridgeBio Oncology merges with Helix Acquisition Corp. II in a $450M SPAC deal, securing $196M from trust account and $260M in PIPE financing led by Cormorant Asset Management.
• The company's lead program BBO-8520 is advancing in Phase I ONKORAS-101 trial for KRASG12C mutant non-small cell lung cancer, alongside two other clinical-stage oncology programs.
• Post-merger entity, valued at $949M, will trade as BBOT with access to approximately $550M cash to accelerate development of its targeted cancer therapy portfolio.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath